ArticleNeuropsychiatric disease and treatment2007
Neurologic uses of botulinum neurotoxin type A.
Article in Neuropsychiatric disease and treatment, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment Effects for Dysphagia in Adults with Multiple Sclerosis: A Systematic Review.Dysphagia · 2016Pooled it
- Trial
- Neuronox versus BOTOX in the Treatment of Post-Stroke Upper Limb Spasticity: A Multicenter Randomized Controlled Trial.PloS one · 2015Trial
- Article
- Efficacy and Safety of Botulinum Toxin Type A (NABOTA) for Post-stroke Upper Extremity Spasticity: A Multicenter Phase IV Trial.Annals of rehabilitation medicine · 2022Article
- Ultrasound-Guided OnabotulinumtoxinA Injections to Treat Oromandibular Dystonia in Cerebral Palsy.Toxins · 2022Article
- Article
- Intramuscular Injection of BOTOX® Boosts Learning and Memory in Adult Mice in Association with Enriched Circulation of Platelets and Enhanced Density of Pyramidal Neurons in the Hippocampus.Neurochemical research · 2020Article
- Bacterial Toxins and Targeted Brain Therapy: New Insights from Cytotoxic Necrotizing Factor 1 (CNF1).International journal of molecular sciences · 2018Review
- AbobotulinumtoxinA: A 25-Year History.Aesthetic surgery journal · 2017Review
- Introduction to the Supplement: A Review of AbobotulinumtoxinA (Dysport).Aesthetic surgery journal · 2017Review
- New Uses of AbobotulinumtoxinA in Aesthetics.Aesthetic surgery journal · 2017Review
- Botulinum Toxin in Pediatric Neurology: Switching Lanes From Death to Life.Global pediatric health · 2015Article
- Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations.Journal of neural transmission (Vienna, Austria : 1996) · 2013Article
- Review
- Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons.Journal of pain research · 2011Article
- Spasticity mechanisms - for the clinician.Frontiers in neurology · 2010Article
- Botulinum toxin - From WMD to therapeutic agent and cosmetic aid.Neuropsychiatric disease and treatment · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reviews the current and most neurologic uses of botulinum neurotoxin type A (BoNT-A), beginning with relevant historical data, neurochemical mechanism at the neuromuscular junction. Current commercial preparations of BoNT-A are reviewed, as are immunologic issues relating to secondary failure of BoNT-A therapy. Clinical uses are summarized with an emphasis on controlled clinical trials (as appropriate), including facial movement disorders, focal neck and limb dystonias, spasticity, hypersecretory syndromes, and pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.